Latest Research News

Get the most up-to-date Research news related to Scleroderma and Raynaud's

Previous Research News

News article - Celebrating World Clinical Trials Day!

20 May 2021 is World Clinical Trials Day to mark the anniversary of the first-ever trial that was conducted in 1747. Today, clinical trials are vital in determining the safety and efficacy of new treatments all over the world. But what happens in a clinical trial, and could you take part?
Find out more

News article - Your Raynaud’s and You – Insights from SRUK’s work on the Raynaud’s App

Can you imagine a world where we could have a greater understanding of Raynaud’s? Have more information on what triggers an attack? Understand how in some cases Raynaud’s combined with other symptoms may be an early predictor of scleroderma? The Raynaud’s ResearchApp, an SRUK-led partnership with app development company Healthbit and data company D4T4, intends to do just this!
Find out more

News article - The Raynaud’s App: the story so far

SRUK is pioneering ‘The Raynaud’s ResearchApp,’ that aims to help identify Raynaud’s patients at risk of developing scleroderma, with a view to achieving earlier diagnosis and improved outcomes. The technology also enables users to record their experiences of Raynaud’s symptoms and learn more about potential triggers. The App has recently been piloted in a clinical trial.
Find out more

News article - A Design for Life: is scleroderma in the genes?

What is the link between our genetic code and developing scleroderma? Researchers from Spain have recently studied genetic alterations and established a connection with the pathways that dictate the clinical features of scleroderma. The study is significant because increasing our understanding of the genetic pathway could be a faster route towards identifying effective new therapies for this complex condition.
Find out more

News article - Open Research - revolutionising the publishing process for SRUK research

SRUK is working with our partners at the Association of Medical Research Charities via their new Open Research Platform, to revolutionise the publishing process for our researchers. This will enable SRUK-funded research groups to publish their work in a streamlined and cost-effective way, with the ultimate goal of translating new knowledge into effective treatments for people living with scleroderma.
Find out more

News article - What's the outcome? Measuring the effectiveness of new treatments in clinical trials

Clinical trials are the only way to ensure that new treatments are effective. But how exactly does the process work? FInd out why 'outcome measures’ and ‘endpoints’ are crucial, and how SRUK funding is playing a key role in improving the measures used in treatments for scleroderma.
Find out more

News article - The Link Between Metabolism and Fibrosis in People With Scleroderma

A new study from the UK has identified a possible connection between metabolism and fibrosis in people with scleroderma, with the potential to open up new treatment avenues in the future.
Find out more

News article - SRUK’s co-funded project with World Scleroderma Foundation seeking to improve the Combined Response Index in SSc Score.

An important part of participating in a project such as this is ensuring that you understand how the collected data will be used and why community input is so valuable and fundamentally vital.
Find out more

News article - Findings of nintedanib's safety and tolerability published

A team of researchers based in the USA, UK, Germany, Switzerland and Japan sought to examine the results of the SENSCIS trial to assess the safety and tolerability of nintedanib in people with SSc-ILD.
Find out more

News article - The CRISTAL Index

SRUK funding is playing a key role in improving how we determine the success of new treatments in clinical trials. These projects aim to better inform researchers of the impact of potential therapies, ultimately improving wellbeing and quality of life for people living with scleroderma.
Find out more

News article - Collaboration is Key: Developing a New Diagnostic Tool for Scleroderma

“We are limited by current assessment tools such as the skin score, which is limited by subjectivity, as well as the time needed for training and standardisation. We need to make sure that new treatments are evaluated in the best and most robust way so that we can make more progress and discontinue approaches that do not work.” Prof. Chris Denton
Find out more

News article - Touching on Touchscreens - Making Technology More Accessible for People With Scleroderma

Are you reading this from a touchscreen device? Using touchscreen technology is something many of us do every day, without even thinking about it. But what happens to the people who have conditions that make touchscreens tough?
Find out more

News article - Could I be at risk? What we know so far about immune responses to the COVID-19 vaccination in those with weakened immune systems

As the UK strives to give every adult their COVID-19 vaccinations, what do we know about their effectiveness in protecting those with weakened immune systems such as some individuals with scleroderma?
Find out more

News article - Utilizing Ultrasound

Dr Victoria Flower was awarded funding by SRUK to research non-invasive methods of skin assessment in scleroderma. Last month, her work was published in The Journal of Rheumatology, discussing the potential use of High Frequency Ultrasound as a more objective and detailed measure of skin involvement in scleroderma.
Find out more

News article - Just in time! UK approves new COVID-19 treatment for immunocompromised individuals

As OCTAVE study sheds light on the reduced immune response in those with chronic illness, the new antibody treatment from Regeneron and Roche could be of great benefit for those who are immunosuppressed or immunocompromised.
Find out more

News article - The OCTAVE Study: Scaling up our understanding of vaccine effectiveness in people living with autoimmune conditions

OCTAVE study reveals how effective COVID-19 vaccinations are in immunocompromised participants
Find out more

News article - 2021 Virtual Conference Round-Up

A series of talks took place throughout the day, covering areas of research funded by SRUK, advice on symptom management, and discussions about the future. This article offers a brief overview of each talk as a taster, and in the coming months they will be made available online.
Find out more

News article - Creating Clinical Trials for Children

: Affecting around 200 children in the UK, Juvenile Localised Scleroderma is an incredibly rare condition. Developing new treatments is challenging due to small numbers of patients. Find out how SRUK and Alder Hey are tackling this!
Find out more

News article - Stratified Medicine - The Latest SRUK Grant Call

What is stratified medicine? Stratified medicine is also known as personalised medicine and works by dividing patients within the larger group into subgroups by factors that make their condition different.
Find out more

News article - UPDATED: Breaking News - NICE approve Nintedanib for use in PF-ILD, which includes SSc Interstitial Lung Disease

SRUK are pleased to announce that NICE have approved the use of Nintedanib in treating progressive fibrosing interstitial lung disease (PF-ILD)!
Find out more

News article - 2021 Flu Season - Are you at risk? Are you eligible for the vaccine?

With autumn now firmly upon us, we are facing the onset of the winter flu season. If you have systemic sclerosis you may be at a higher risk if you catch the flu. What can you do to protect yourself?
Find out more

News article - First take at home COVID-19 antiviral treatments approved for vulnerable adults

Yesterday, the UK’s Medicine and Health products Regulation Agency approved the world’s first ‘take at home’ COVID-19 treatment, Lagevrio – one of two antiviral treatments secured by the UK Government in October.
Find out more

News article - Omicron - The Latest COVID-19 Variant: Should I be Worried?

A new COVID-19 variant originating from South Africa is making headlines due to its large number of mutations and the risk they pose. Designated as a ‘variant of concern’ by WHO, how worried do we need to be about the Omicron variant, and what do you need to be aware of?
Find out more

News article - Increasing access to COVID-19 treatment for those most vulnerable

On the 8th December the UK government announced several measures to ensure those who are most at risk from COVID-19 are given access to new treatments within their community, and where possible, within their own home.
Find out more

News article - A Gut Feeling: The Microbiome and Scleroderma

At the 2021 SRUK Virtual Conference Dr Elizabeth Volkmann presented a very popular session on Understanding Gastrointestinal Involvement in Scleroderma – where she introduced the concept of how a person’s microbiome might influence their condition. This article takes a deeper dive into the world of the microbiome.
Find out more

News article - Fast-forward to 2040: What does the future hold for Scleroderma?

As we come to the end of 2021, SRUK have been thinking about the new year, and the one after that… and the one after that. In just 12 months, we have seen huge change across the world, which got us thinking, what could things look like in 20 years?
Find out more